All News

CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.

Your daily dose of the clinical news you may have missed.

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Topical corticosteroids, once revolutionary for treatment of atopic dermatitis, are used just sparingly today; dermatologist Mona Shahriari, MD, lists the reasons.

New phase 3b data suggest that a modified titration of donanemab reduces the risk of brain swelling and fluid accumulation at 24 weeks.

Your daily dose of the clinical news you may have missed.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.